SUO Annual Meeting

The Cancer Genome Atlas (TCGA) has provided a “complete genomic roadmap” of muscle-invasive bladder cancer, according to Seth P. Lerner, MD, co-chair of the Analysis Working Group of the TCGA program for muscle-invasive bladder cancer. Dr. Lerner talks to Urology Times about the clinical relevance of the TCGA’s findings, possible implications for upper tract disease, and what further research is needed.

The introduction of targeted therapies and immunotherapies has generated uncertainty regarding the role of the cytoreductive nephrectomy in the treatment of metastatic renal cell carcinoma. In this interview, Hyung L. Kim, MD, discusses the recent CARMENA and SURTIME clinical trials, and outlines the upcoming SWOG-1931 trial.

In a pivotal phase III study, more than half of patients with high-grade nonmuscle-invasive bladder cancer (carcinoma in situ ± Ta/T1) receiving nadofaragene firadenovec achieved a complete response at 3 months, reported lead author Colin P.N. Dinney, MD.

Christopher Sweeney, MBBS, outlines a handful of important questions to ask when deciding which systemic therapy to select for which patient with metastatic hormone-sensitive prostate cancer.

“I think it’s time to realize that there are other options besides cystectomy, and that the other options should at least be discussed and entertained,” says Alexandre Zlotta, MD, PhD, in this video.

“Over the past few decades, the rate of active surveillance has been around 10%. Now in recent years, the rate of active surveillance is 55% across the U.S. So times are changing," says Sigrid Carlsson, MD, PhD, MPH, in this interview.

In this video, Viraj Master, MD, offers the latest evidence and his recommendations for managing synchronous and metachronous disease in the face of renal cell carcinoma, including the role of metastasectomy.

In this video interview with Urology Times, Arjun V. Balar, MD, PhD, discusses the current role of PD-1 inhibitors, their mechanism of action, and his own impression of recently presented phase II study data.

“Urologists can play an active role in reducing the opioid epidemic just by prescribing fewer opioids,” says Kathryn Hacker Gessner, MD, PhD, in this video.

In this video, Todd M. Morgan, MD, talks about the still-uncertain future of imaging in advanced prostate cancer.

In a video interview with Urology Times, Robert C. Flanigan, MD, points out the shortcomings of the CARMENA trial, patient selection for cytoreduction, and the future of cytoreductive nephrectomy in the age of PD-1 inhibitors.

In this video, Inderbir S. Gill, MD, discusses data comparing multiple parameters, including intraoperative, perioperative, oncologic, and functional outcomes of open versus robotic surgery

"Urologists in practice now need to have at least some working knowledge in this area because I’ve seen it several times in my academic practice," says one urologist.

Compared with other treatment approaches, definitive surgical extirpation provides the best survival outcomes in patients with invasive, non-urachal adenocarcinoma of the bladder, results of a recent study suggest.